Literature DB >> 17112602

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

A C Hurt1, P Selleck, N Komadina, R Shaw, L Brown, I G Barr.   

Abstract

Since 2003, highly pathogenic A(H5N1) influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. A group of 55 influenza A(H5N1) viruses isolated from various regions of South East Asia between 2004 and 2006 were tested for their susceptibility to the anti-influenza drugs the neuraminidase inhibitors and adamantanes. The majority of strains were found to be fully sensitive to the neuraminidase inhibitors oseltamivir carboxylate, zanamivir and peramivir; however two strains demonstrated increased IC50 values. Sequence analysis of these strains revealed mutations in the normally highly conserved residues 116 and 117 of the N1 neuraminidase. Sequence analysis of the M2 gene showed that all of the A(H5N1) viruses from Vietnam, Malaysia and Cambodia contained mutations (L26I and S31N) associated with resistance to the adamantane drugs (rimantadine and amantadine), while strains from Indonesia were found to be a mix of both adamantane resistant (S31N) and sensitive viruses. None of the A(H5N1) viruses from Myanmar contained mutations known to confer adamantane resistance. These results support the use of neuraminidase inhibitors as the most appropriate class of antiviral drug to prevent or treat human A(H5N1) virus infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112602     DOI: 10.1016/j.antiviral.2006.10.004

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  82 in total

1.  Emergence of amantadine-resistant avian influenza H5N1 virus in India.

Authors:  C Tosh; H V Murugkar; S Nagarajan; S Tripathi; M Katare; R Jain; R Khandia; Z Syed; P Behera; S Patil; D D Kulkarni; S C Dubey
Journal:  Virus Genes       Date:  2010-10-16       Impact factor: 2.332

Review 2.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

3.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

4.  In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Authors:  Katrina Sleeman; Vasiliy P Mishin; Varough M Deyde; Yousuke Furuta; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

5.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

6.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970

7.  Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2.

Authors:  Mohamed Rajik; Fatemeh Jahanshiri; Abdul Rahman Omar; Aini Ideris; Sharifah Syed Hassan; Khatijah Yusoff
Journal:  Virol J       Date:  2009-06-05       Impact factor: 4.099

8.  Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.

Authors:  Natalia A Ilyushina; Jon P Seiler; Jerold E Rehg; Robert G Webster; Elena A Govorkova
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

9.  Threat of an influenza pandemic: family physicians in the front line.

Authors:  Wim Opstelten; Jim E van Steenbergen; Gerrit A van Essen; Marianne A B van der Sande
Journal:  BMC Fam Pract       Date:  2009-02-03       Impact factor: 2.497

10.  A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells.

Authors:  Mohamed Rajik; Abdul Rahman Omar; Aini Ideris; Sharifah Syed Hassan; Khatijah Yusoff
Journal:  Int J Biol Sci       Date:  2009-08-08       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.